Choksi Laboratories to hold 33rd AGM via video conference on August 21

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Choksi Laboratories to hold 33rd AGM on August 21, 2026
  • Meeting conducted via Video Conferencing or Other Audio Visual Means
  • Intimation issued under Regulation 47 of SEBI LODR Regulations
  • Shareholders urged to register email IDs for virtual participation
powered bylight_fuzz_icon
48842841

*this image is generated using AI for illustrative purposes only.

Choksi Laboratories will hold its 33rd Annual General Meeting on August 21, 2026. The meeting will be conducted through Video Conferencing or Other Audio Visual Means.

The company issued the intimation pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. An advertisement was published in the English edition of Free Press Journal and the Hindi edition of Choutha Sansar on August 21, 2026.

Shareholder Instructions

The notice informs shareholders about the manner to register their email IDs if they have not already done so with the Company or their Depository Participants. This registration is necessary for participation in the virtual meeting.

Prakhar Dubey, Company Secretary and Compliance Officer, signed the communication addressed to the General Manager of the Corporate Relationship Department at The Bombay Stock Exchange Limited.

Historical Stock Returns for Choksi Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+1.10%+13.35%+21.55%+22.60%-40.49%+695.83%

What key strategic initiatives or financial resolutions are expected to be tabled for shareholder approval at the upcoming AGM?

How might the continued adoption of virtual meetings via Video Conferencing impact Choksi Laboratories' shareholder engagement and participation rates?

Are there any anticipated changes to the board of directors or executive compensation structures that will be discussed during the meeting?

Choksi Laboratories net profit up 51% in Q1FY27 to ₹58.24 lakh

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights

Choksi Laboratories posted a 51% YoY jump in net profit to ₹58.24 lakh for Q1FY27, aided by significant tax credits. Revenue grew 7% to ₹1,207.89 lakh, while PBT dipped 4.5% due to rising expenses. The board also approved key governance changes.

powered bylight_fuzz_icon
48166521

*this image is generated using AI for illustrative purposes only.

Choksi Laboratories reported a net profit of ₹58.24 lakh for the quarter ended June 30, 2026, rising 51% from ₹38.50 lakh in the same period last year. Total revenue from operations increased 7% year-on-year to ₹1,207.89 lakh, up from ₹1,124.52 lakh in Q1FY25.

The company’s Board of Directors approved the unaudited financial results on August 13, 2026. The results were reviewed by Prateek Jain & Co., who issued a limited review report with no qualifications. The financials were prepared in accordance with Ind AS 34 and SEBI LODR regulations.

Financial Performance

Revenue from operations stood at ₹1,206.29 lakh, compared to ₹1,124.19 lakh in the corresponding quarter of FY25. Other operating revenue contributed ₹1.60 lakh. Total expenses were ₹1,147.96 lakh, leading to an operating profit before tax of ₹59.93 lakh.

Metric: Q1FY26 (₹ in Lakhs) Q1FY25 (₹ in Lakhs) Change:
Revenue from Operations: 1,206.29 1,124.19 +7.3%
Total Revenue: 1,207.89 1,124.52 +7.4%
Total Expenses: 1,147.96 1,061.78 +8.1%
Profit Before Tax: 59.93 62.74 -4.5%
Net Profit: 58.24 38.50 +51.3%

Earnings per share (basic and diluted) were ₹0.84, compared to ₹0.55 in the previous year’s corresponding quarter. For the full fiscal year ended March 31, 2026, the company reported total revenue of ₹4,621.93 lakh and a net profit of ₹196.43 lakh.

What the Numbers Show

While profit before tax declined slightly by 4.5% to ₹59.93 lakh due to higher operating expenses, the net profit surged 51% year-on-year. This divergence is primarily driven by favorable tax adjustments. Deferred tax expenses showed a credit of ₹16.30 lakh in Q1FY26, compared to a debit of ₹12.43 lakh in Q1FY25. Additionally, mat credit utilization resulted in a benefit of ₹8.54 lakh, contrasting with a charge of ₹1.88 lakh in the prior year. These tax-related items significantly boosted the bottom line despite modest operational profitability.

Corporate Actions

The Board approved several administrative and governance measures:

  • Re-appointed Ms. Himika Choksi as Whole Time Director for five years, effective April 1, 2027, subject to shareholder approval.
  • Scheduled the 33rd Annual General Meeting for September 18, 2026, via video conferencing.
  • Set the register closure period from September 12 to September 18, 2026.
  • Re-appointed M/s Tanmay V. Rajurkar & Co. as Internal Auditor for FY27.
  • Changed the Registrar and Share Transfer Agent from MUFG Intime India Private Limited to Ankit Consultancy Private Limited.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE493D01013/e761f0f8-8675-45ef-b4b5-c3be05550cc4.pdf

Historical Stock Returns for Choksi Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+1.10%+13.35%+21.55%+22.60%-40.49%+695.83%

Will Choksi Laboratories be able to sustain the 51% net profit growth in upcoming quarters without relying on favorable tax adjustments and MAT credit benefits?

How does the 8.1% rise in total expenses compare to industry peers, and what specific cost-control measures are planned to improve operating margins?

What is the strategic rationale behind switching the Registrar and Share Transfer Agent to Ankit Consultancy Private Limited, and will this impact shareholder services?

More News on Choksi Laboratories

1 Year Returns:-40.49%